GMP-grade In Vitro Transcription (IVT) system buffers are well-defined aqueous formulations manufactured under Good Manufacturing Practice (GMP) conditions. They are used in enzymatic, cell-free RNA synthesis reactions in which RNA polymerases, most commonly bacteriophage-derived enzymes such as T7 RNA polymerase, transcribe RNA from a DNA template. IVT is widely described in peer-reviewed literature as a core platform technology for the production of research-grade and therapeutic RNA, including mRNA and saRNA.
Biological Significance
- Enable template-directed RNA synthesis, forming the basis for in vitro production of mRNA used in vaccines, gene expression studies, and RNA functional assays.
- Support reaction conditions that influence RNA yield, length fidelity, and integrity, which are critical for downstream biological performance and reproducibility.
- Provide controlled biochemical environments (pH, ionic strength, and cofactor availability) required for optimal activity of RNA polymerases such as T7 RNA polymerase.
- Contribute to reduction of reaction variability when used within controlled and validated IVT manufacturing workflows.
Utility in GMP Manufacturing
- Support scalable IVT workflows for the production of therapeutic RNA under controlled manufacturing conditions.
- Provide standardized formulation parameters that contribute to process consistency when combined with qualified enzymes, nucleotide triphosphates (NTPs), and defined DNA templates.
- Are manufactured and documented under GMP systems, supporting traceability, batch record control, and quality assurance requirements applicable to clinical-grade production.
- Integrate into downstream processing workflows, including enzymatic or co-transcriptional capping, purification, and formulation of mRNA drug substances.
Key Features of GMP-grade IVT Buffers
- Defined composition (commonly including buffering agents such as Tris, magnesium salts, and reducing agents such as DTT), optimized for enzymatic transcription efficiency.
- Manufactured under RNase-controlled conditions to minimize RNA degradation risk.
- Controlled bioburden and endotoxin specifications appropriate for therapeutic manufacturing use cases.
- Batch-to-batch consistency supported by GMP documentation, quality control testing, and release criteria.
- Compatible with modified nucleotides (e.g., nucleoside-modified RNA) used in therapeutic mRNA and saRNA applications.
